A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/425 (2006.01) A61K 31/282 (2006.01) A61K 31/337 (2006.01) A61K 31/4745 (2006.01) A61K 31/505 (2006.01) A61K 31/70 (2006.01) A61K 33/24 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2495962
This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of adminestering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane derivative, a platinium coordination complex selected from the group consisting of carboplatin, tetraplatin, and topotecan, a nucleoside analog selected from the group consisting of gemcitabine, hydrochloride and 5-FU, an anthracycline, a topoisomerase selected from the group consisting of etoposide, teniposide, amsacrine, topotecan and CamptosarÚ, an aromatase inhibitor; and (ii) a therapeutically effective amount of an isothiazole derivative. The combinations of the present invention may optionally include an anti- hypertensive agent. This invention also relates to pharmaceutical compositions useful in the treatment of hyperproliferative diseases in mammals, containing such combinations. The present invention also relates to kits having a first compartment with a compound of formula 1 and a second compartment containing a taxane derivative, a platinum coordination complex, a nucleoside analog, an anthracycline, a topoisomerase inhibitor, or an aromatase inhibitor and a third compartment containing an anti-hypersensitive agent.
L'invention concerne un procédé de traitement de maladies hyperprolifératives. Elle concerne, plus particulièrement, un procédé de traitement de maladies hyperprolifératives, telles que le cancer, consistant à administrer à un mammifère, nécessitant un tel traitement, soit simultanément, soit séquentiellement, (I) une quantité, efficace sur le plan thérapeutique, d'un dérivé de taxane, d'un complexe de coordination du platine sélectionné parmi le groupe comprenant des complexes carboplatine, tétraplatine, et topotécane, d'un analogue de nucléoside sélectionné parmi le groupe d'analogues comprenant l'hydrochlorure de gemcitabine ou le 5-fluoro-uracile, d'une anthracycline, d'un inhibiteur de topoisomérase sélectionné parmi le groupe comprenant étoposide, téniposide, amsacrine, topotécane et Camptosar ??¿, d'un inhibiteur d'aromatase, et (ii) une quantité, efficace sur le plan thérapeutique, d'un dérivé d'isothiazole. Les combinaisons de l'invention peuvent éventuellement contenir un agent antihypertenseur. L'invention concerne encore aussi des compositions pharmaceutiques contenant de telles combinaisons, utiles dans le traitement de maladies hyperprolifératives chez les mammifères. Elle concerne enfin des kits comportant un premier compartiment contenant un composé de formule (I) et un deuxième compartiment contenant un dérivé de taxane, un complexe de coordination du platine, un analogue de nucléoside, une anthracycline, un inhibiteur de topoisomérase, ou un inhibiteur d'aromatase et un troisième compartiment contenant un agent antihypertenseur.
Beebe Jean Saccuzzo
Ferrante Karen Jean
Healey Diane Ingeborg
Jani Jitesh Pranlal
O'leary James John
Osi Pharmaceuticals Inc.
Pfizer Inc.
Pfizer Products Inc.
Smart & Biggar
LandOfFree
Combination therapy for hyperproliferative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for hyperproliferative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for hyperproliferative diseases will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1811278